AE Management With TKIs and Belzutifan
A panelist discusses how managing adverse events associated with TKIs and belzutifan requires a proactive approach encompassing prevention strategies, regular monitoring, dose modifications when needed (particularly for combination regimens), and evidence-based mitigation techniques, while considering the distinct toxicity profiles of each agent and the impact of dose adjustments on treatment efficacy.
Video content above is prompted by the following:
- What advice can you offer to community oncologists with respect to management of AEs associated with TKIs or belzutifan?
- How do the toxicities of TKIs compare with those of belzutifan?
- How do you prevent, monitor, mitigate, and manage treatment-associated toxicities?
- How do you handle dose modifications
- For tivozanib
- Other options (eg, len/eve)
- How do you decide which drug to modify when using a combination regimen?
- What is the data on efficacy of these therapies with reduced dosages
Ruxolitinib Effective as Second-Line Therapy for Chronic GvHD
July 15th 2021In an interview with Targeted Oncology, Stephanie Lee, MD, MPH, reviewed the updated data from the REACH3 trial along with the efficacy of ruxolitinib in the greater chronic graft versus host disease population.
Read More
Clinical Treatment Act Aims to Improve Survival, Close Racial Health Care Gap
June 28th 2021Across the United States, the health insurance coverage gap continues to impact millions of patients who are largely low-income or are racial minorities. After years of lobbying, Congress has passed the Clinical Treatment Act, which is legislation designed to improve access to health coverage.
Read More
